• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Merck Kgaa ADR (OP: MKKGY )

    29.08 -0.02 (-0.07%)
    Streaming Delayed Price Updated: 3:59 PM EST, Dec 27, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 125,120
    Open 29.02
    Bid (Size) N/A (0)
    Ask (Size) N/A (0)
    Prev. Close 29.10
    Today's Range 28.94 - 29.16
    52wk Range 28.29 - 39.17
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Pfizer Clears Required Regulatory Hurdles To Complete $43B Seagen Acquisition
    Pfizer Inc (NYSE: PFE)  
    Via Benzinga
    Merck Germany's Two Pivotal Trials Flunk In Multiple Sclerosis
    Merck KGaA (OTC: MKGAF) (OTC:  
    Via Benzinga

    Performance

    YTD
    -6.53%
    -6.53%
    1 Month
    -2.71%
    -2.71%
    3 Month
    -17.81%
    -17.81%
    6 Month
    -10.72%
    -10.72%
    1 Year
    -8.93%
    -8.93%

    More News

    Read More
    Life Sciences Player Repligen's Strategic European Acquisition - What It Means for Investors
    Via Benzinga
    Merck Germany Reports 5% Decline In Q2 Sales, Expects More Decline In 2023
    Via Benzinga
    Novo Nordisk's Obesity Drug Saxenda Not Included In WHO's Essential Drug List
    Via Benzinga
    Germany's Merck To Launch Semiconductor Base In China
    Via Benzinga
    Abcam Downgrade: Analyst Trims Expectations Amid Activist Investor Engagement and Potential Bid Anticipation
    Via Benzinga
    Analyst Says Nektar Therapeutics' Rezpeg Prioritization Likely to Spark Investor Questions
    Via Benzinga
    FDA Issues Partial Clinical Hold On Merck Germany's Multiple Sclerosis Study
    Via Benzinga
    Merck Germany Regains Exclusive Global Rights To Cancer Drug From Pfizer
    Via Benzinga
    Incyte Would Now Compete With Merck, Pfizer As Its Skin Cancer Treatment Scores FDA Accelerated Approval
    Via Benzinga
    With Upcoming Ovarian Cancer Data, Analyst Sees 100% Upside For Mersana Therapeutics
    Via Benzinga
    PDS Biotech, Merck Germany Enter Licensing Pact For Investigational Cancer Treatment
    Via Benzinga
    Mersana Inks Cancer Therapy Development Deal With Merck Germany
    Via Benzinga
    SpaceX Starlink's New In-Flight Connectivity Service, Amazon's NY Workers Reject Union, Celsius Network Faces Several Federal Investigations: Top Stories Wednesday, Oct. 19
    Via Benzinga
    Germany's Merck Slapped With Formal French Investigation Related To Its Thyroid Drug
    Via Benzinga
    PDS Biotech Highlights Expanded Data From PDS0101 Triple Combination Trial In HPV-Positive Cancers
    Via Benzinga
    TSM Looks To Hire Over 8,000 People In 2022
    Via Benzinga
    Despite Palantir’s Impressive Deals, Its Losses and Valuation Make It Unappetizing
    Via InvestorPlace
    The Daily Biotech Pulse: Pfizer Strikes $5.29B COVID Pill Supply Deal With US, Roche's Spark Therapeutics Reports Positive Gene Therapy Readout, EDAP Earnings
    Via Benzinga
    GlaxoSmithKline, Merck KGaA End $4B Cancer Drug Pact
    Via Benzinga
    Nektar, Merck Germany, Pfizer Join Forces For Mid-Stage Bladder Cancer Study
    Via Benzinga
    Merck KGaA Pulls Plug On GSK-Partnered Cancer Drug Trial
    Via Benzinga
    Sutro Biopharma Receives Undisclosed Milestone Payment Under Bispecific ADC Collaboration with Merck
    Via Benzinga
    Immutep, Merck Germany Team Up for Eftilagimod/Bintrafusp Combo Trial In Solid Tumors
    Via Benzinga
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.